Mallinckrodt’s muscular dystrophy drug receives FDA fast track designation
The US Food and Drug Administration (FDA) has granted Mallinckrodt’s request for a fast track designation for synacthen depot for the treatment of Duchenne muscular dystrophy (DMD).
Click on this link for more information.
